Immuron Travelan highest sales in history
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The report highlights a significant increase in sales globally, with notable growth in North America and Australia despite some quarterly fluctuations. The filing is authorized by the directors of Immuron Limited, confirming its authenticity and compliance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immuron
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan continued strong sales growth
- Immuron Announces Travelan Clinical Trial Update
- NMRC Reports Results for Campylobacter Clinical Study
Later from Immuron
- FY25 global sales exceed projection, up 49% on prior year
- Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
- Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
- Immuron partners with InvestorHub
- Appendix 4E Preliminary Final Report
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron